Lexeo Therapeutics, INC DEF 14A proxy statements
Proxy statements, covering the matters put to shareholders at the annual meeting — board elections, auditor ratification and executive pay.
NASDAQ
Lexeo Therapeutics announces its 2026 Annual Meeting of Stockholders, scheduled for June 25, 2026, to elect directors and ratify auditors.
NASDAQ
DEFA14A: Lexeo Therapeutics Amends Non-Employee Director Compensation Policy, Increasing Equity Awards
Lexeo Therapeutics, Inc. has filed a proxy statement supplement detailing an amendment to its non-employee director compensation policy, increasing equity awards for eligible directors.
NASDAQ
LEXEO Therapeutics announces its 2025 Annual Meeting of Stockholders to be held on June 26, 2025, outlining key proposals for voting.
NASDAQ
Lexeo Therapeutics announces its 2025 Annual Meeting of Stockholders to be held virtually on June 26, 2025, featuring proposals for director elections and ratification of the independent accounting firm.
NASDAQ
DEFA14A: Lexeo Therapeutics Sets Date for 2024 Annual Meeting, Outlines Proposals for Stockholder Vote
Lexeo Therapeutics has scheduled its annual stockholder meeting for June 25, 2024, with proposals including the election of a Class I director and ratification of KPMG LLP as the independent auditor.
NASDAQ
Lexeo Therapeutics announces its 2024 Annual Meeting of Stockholders to be held virtually on June 25, 2024, featuring proposals for director election and auditor ratification.